Athanasius Ishak
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Athanasius Ishak has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Akshaya Rajangam
Faculty of Life Sciences and Medicine, Centre for Human and Applied Physiological Science (CHAPS), King's College London, Strand, London, WC2R 2LS, UK
2 shared publications - Ankur Khajuria
Department of Surgery and Cancer, Imperial College London, London, United Kingdom
2 shared publications - Joerg Steier
Centre for Human and Applied Physiological Sciences (CHAPS), Faculty of Life Sciences and Medicine, King's College London, London, UK
1 shared publication Michelle Ramsay
Lane Fox Respiratory Unit, Guy's and St Thomas' NHS Foundation Trust, London, UK
1 shared publication- Nicholas Hart
King's College London, London, UK
1 shared publication
Latest Publications
- Open Access
- 1 July 2020
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 55, 212
Evidence base for the management of flexor tendon injuries
- 1 July 2020
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 55, 212
Open AccessEvidence base for the management of flexor tendon injuries
- Open Access
- 1 December 2019
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 48, 1-6
The evidence-base for the management of flexor tendon injuries of the hand: Review
•There is no consensus on the optimal flexor tendon repair technique at each anatomical flexor zone.•There is paucity of high quality evidence.•Heterogenous study designs limit inter-study comparisons.•Patient reported outcome measures are crucial but there is a perennial need for robust disease-specific tools to be utilised.
- 1 December 2019
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 48, 1-6
Open AccessThe evidence-base for the management of flexor tendon injuries of the hand: Review
•There is no consensus on the optimal flexor tendon repair technique at each anatomical flexor zone.•There is paucity of high quality evidence.•Heterogenous study designs limit inter-study comparisons.•Patient reported outcome measures are crucial but there is a perennial need for robust disease-specific tools to be utilised.
- 12 August 2019
- Published by Wiley in Respirology
- Vol. 25 (4) , 443-448
BPAP is an effective second‐line therapy for obese patients with OSA failing regular CPAP: A prospective observational cohort study
Background and objective: Continuous positive airway pressure (CPAP) is the most common treatment for obstructive sleep apnoea (OSA), but many patients fail long‐term therapy. Bilevel positive airway pressure (BPAP) is a potential alternative. We hypothesized that BPAP could improve treatment adherence and outcomes in patients who cannot tolerate CPAP.Methods: Patients with OSA who failed CPAP (usage < 4 h/day) and were referred to a tertiary sleep centre between 2014 and 2017 for BPAP were included. Age, gender, body mass index (BMI), co‐morbidities, CPAP use and reasons for failure, Epworth Sleepiness Scale (ESS), sleep study data, spirometry data and average maximum nightly compliance were recorded.Results: A total of 52 patients with OSA requiring CPAP > 15 cm H2O (71% male, age: 58 (15) years, BMI: 42.6 (10.1) kg/m2, apnoea–hypopnoea index (AHI): 51.1 (30.4)/h) were studied; 62% had respiratory co‐morbidities affecting nocturnal breathing including obesity hypoventilation syndrome and COPD; 25% had neuromuscular conditions; and 17% had cardiovascular disease. CPAP was used for 199 (106–477) days prior to referral for BPAP. Reasons for CPAP failure were intolerant pressures (23%), uncontrolled symptoms (23%), mask problems (21%), adverse effects (13%), claustrophobia (8%), co‐morbidities (8%) and other issues (4%). Lower expiratory positive airway pressures were needed with BPAP compared to CPAP (10 (8–12) vs 16.8 (15.7–19.2) cm H2O, P = 0.001); patients achieved better adherence to BPAP (7.0 (4.0–8.5) vs 2.5 (1.6–6.7) h/night, P = 0.028) and better symptom control (ESS: 4.0 (1.0–7.0) vs 10.0 (6.0–17.0) points, P = 0.039).Conclusion: In patients with moderate–severe OSA who fail CPAP therapy due to low adherence, BPAP is well tolerated and achieves sufficient control of sleep‐disordered breathing and its symptoms.
- 12 August 2019
- Published by Wiley in Respirology
- Vol. 25 (4) , 443-448
BPAP is an effective second‐line therapy for obese patients with OSA failing regular CPAP: A prospective observational cohort study
Background and objective: Continuous positive airway pressure (CPAP) is the most common treatment for obstructive sleep apnoea (OSA), but many patients fail long‐term therapy. Bilevel positive airway pressure (BPAP) is a potential alternative. We hypothesized that BPAP could improve treatment adherence and outcomes in patients who cannot tolerate CPAP.Methods: Patients with OSA who failed CPAP (usage < 4 h/day) and were referred to a tertiary sleep centre between 2014 and 2017 for BPAP were included. Age, gender, body mass index (BMI), co‐morbidities, CPAP use and reasons for failure, Epworth Sleepiness Scale (ESS), sleep study data, spirometry data and average maximum nightly compliance were recorded.Results: A total of 52 patients with OSA requiring CPAP > 15 cm H2O (71% male, age: 58 (15) years, BMI: 42.6 (10.1) kg/m2, apnoea–hypopnoea index (AHI): 51.1 (30.4)/h) were studied; 62% had respiratory co‐morbidities affecting nocturnal breathing including obesity hypoventilation syndrome and COPD; 25% had neuromuscular conditions; and 17% had cardiovascular disease. CPAP was used for 199 (106–477) days prior to referral for BPAP. Reasons for CPAP failure were intolerant pressures (23%), uncontrolled symptoms (23%), mask problems (21%), adverse effects (13%), claustrophobia (8%), co‐morbidities (8%) and other issues (4%). Lower expiratory positive airway pressures were needed with BPAP compared to CPAP (10 (8–12) vs 16.8 (15.7–19.2) cm H2O, P = 0.001); patients achieved better adherence to BPAP (7.0 (4.0–8.5) vs 2.5 (1.6–6.7) h/night, P = 0.028) and better symptom control (ESS: 4.0 (1.0–7.0) vs 10.0 (6.0–17.0) points, P = 0.039).Conclusion: In patients with moderate–severe OSA who fail CPAP therapy due to low adherence, BPAP is well tolerated and achieves sufficient control of sleep‐disordered breathing and its symptoms.